Clinical Trial Update: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide with low-dose dexamethasone and rituximab in rituximab-resistant, non-aggressive B-cell lymphomas; completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Lymphoma Small Lymphocytic
• Lymphoma of Mucosa-associated Lymphoid Tissue
• Malt Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone B-cell Lymphoma
• Waldenstrom Macroglobulinemia

Drugs mentioned

• Lenalidomide (lenalidomide)
• Revlimid (lenalidomide)
• Rituximab (rituximab)
• low-dose dexamethasone (dexamethasone)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-07